Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03741868
Other study ID # IRB00046256
Secondary ID CCCWFU01517P30CA
Status Completed
Phase
First received
Last updated
Start date October 16, 2016
Est. completion date February 1, 2019

Study information

Verified date July 2020
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Doctors are recruiting patients receiving care for lung cancer at the Wake Forest Baptist Comprehensive Cancer Center asking about needs and experiences during immunotherapy. Immunotherapy is a new treatment for lung cancer. The research is to better understand patients' perspectives on what immunotherapy is like and will provide important information to help understand the symptoms patients experience, the impact of treatment on daily life, ways that people adapt to the challenges of treatment, and services that may help people live better during treatment.


Description:

The overall primary objective of this pilot study is to describe patient-reported symptom burden, unmet supportive care needs, and use of and interest in supportive care services in stage IV non-small cell lung cancer patients undergoing first or second line immunotherapy and to identify psychosocial factors associated with these outcomes.

60 stage IV non-small cell lung cancer patients will be recruited through the Wake Forest Baptist Comprehensive Cancer Center. The study team will use purposive sampling to assure representation of patients at different stages in immunotherapy (i.e., initiating treatment, anticipating scan results, after onset of immune-related side effects).


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 1, 2019
Est. primary completion date July 19, 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed stage IV (per AJCC 7th edition) non-small cell lung cancer.

- Receiving first or second line immunotherapy.

- ECOG Performance status of 0-3.

- English-speaking

Exclusion Criteria:

- Unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Laurie E Steffen Winston-Salem North Carolina
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (3)

Lead Sponsor Collaborator
Wake Forest University Health Sciences Lung Cancer Initiative of North Carolina, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Steffen McLouth LE, Lycan TW Jr, Levine BJ, Gabbard J, Ruiz J, Farris M, Grant SC, Pajewski NM, Weaver KE, Petty WJ. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinica — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary NCI-PRO-CTCAE items The NCI-PRO-CTCAE questionnaire will measure patient reported immune-mediated side effect frequency, severity, and interference of selected symptoms on a varied 1-5 scale with lower scales denoting better outcomes. Higher scores reflect greater symptom severity Past 7 days prior to completion of survey
Primary PROMIS Fatigue The PROMIS Fatigue questionnaire will measure patient reported fatigue on a varied 1-5 scale with lower scales denoting better outcomes. 8 items responded to on a 1-5 likert type scale, with higher scores reflecting greater fatigue. Past 7 days prior to completion of survey
Primary EORTC-QLQ-30 questionnaire EORTC-QLQ-30 questionnaire will measure the patient-reported disease and treatment related symptom severity and interference of 5 functional subscales and 9 symptom subscales. Items are rated on a four-point scale with 1 = not at all to 4 = very much. Subscales are transformed linearly to have a range of 0-100, with higher scores reflecting better function on the 5 functional scales or a higher symptom burden on the symptom scales Past 7 days prior to completion of survey or 7 days after completion of survey
Primary Functional Assessment of Chronic Illness Therapy - Comprehensive Score for Financial Toxicity (FACIT-COST) The FACIT-COST will measure patient reported financial toxicity on a 0 (not at all) - 4 (very much) scale with higher scores denoting better outcomes. Scores calculated following the FACIT scoring procedures such that a higher score represents less financial distress. Past 7 days prior to completion of survey
Primary Supportive Care Needs Survey-Short Form 34 (SCNSF34) questionnaire The Supportive Care Needs Survey-Short Form 34 questionnaire will measure unmet supportive care needs with a scale of 1 (not applicable) to 5 (high need) with lower score indicating better outcome. Responses are provided on a divided 5-point Likert scale (no unmet need indicated by 1 = not applicable or 2 = satisfied; unmet need indicated by 3 = low need, 4 = moderate need, or 5 = high need). The measure contains 5 domains: health system and information, patient care and support, physical and daily living, psychological, and sexual. Past 30 days prior to completion of survey
Secondary PROMIS Short Form Depression PROMIS Short Form Depression will measure distress on a 1 (never) to 5 (always) scale with lower scores denoting better outcome on a 5-point likert-type scale. Higher scores reflect higher distress. Past 7 days prior to completion of survey
Secondary Prognosis Treatment and Perceptions Questionnaire Prognosis Treatment and Perceptions Questionnaire will measure the treatment expectations and prognostic understanding using 8 items with varied response options.. Day 1 of completion of survey
See also
  Status Clinical Trial Phase
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Completed NCT04508270 - Significance of Early Mobilization After VATS-L
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT05469425 - Home-based Preoperative Exercise Training for Lung Cancer Patients Undergoing Surgery N/A
Recruiting NCT05046067 - Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery N/A
Terminated NCT03090880 - Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE) Phase 3
Recruiting NCT05596760 - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers N/A
Completed NCT02498860 - Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung Phase 2
Completed NCT02952261 - Application of 3D Printing Technique in Small Pulmonary Nodule Localization N/A
Not yet recruiting NCT06024538 - Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies
Recruiting NCT02965300 - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis N/A
Completed NCT02616211 - An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Recruiting NCT00765986 - Pilot Study of 18F-FAZA in Assessing Early Functional Response in Patients With Inoperable Non Small Cell Lung Cancer Undergoing Radiotherapy or Chemo-radiotherapy N/A
Completed NCT03320044 - Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
Recruiting NCT03655015 - Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Not yet recruiting NCT05179408 - Telerehabilitation Following Lung Cancer N/A
Completed NCT03749512 - NLCR in Prediction of the Grade of Lung Tumor.
Recruiting NCT03664843 - Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
Completed NCT01261507 - Reader Study of DeltaView™ Chest Radiograph Software N/A
Terminated NCT01064050 - Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers Phase 4